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Background: Metastasis is characterized by spreading of neoplastic cells to an organ other than where they
originated and is the predominant cause of death among cancer patients. This holds true for melanoma, whose
incidence is increasing more rapidly than any other cancer and once disseminated has few therapeutic options.
Here we performed whole exome sequencing of two sets of matched normal and metastatic tumor DNAs.
Results: Using stringent criteria, we evaluated the similarities and differences between the lesions. We find that in
both cases, 96% of the single nucleotide variants are shared between the two metastases indicating that clonal
populations gave rise to the distant metastases. Analysis of copy number variation patterns of both metastatic sets
revealed a trend similar to that seen with our single nucleotide variants. Analysis of pathway enrichment on tumor
sets shows commonly mutated pathways enriched between individual sets of metastases and all metastases
combined.
Conclusions: These data provide a proof-of-concept suggesting that individual metastases may have sufficient
similarity for successful targeting of driver mutations.Background
Cancer is mainly a genetic disease with mutations arising
that can either activate proto-oncogenes or inactivate
tumor suppressor genes. The incidence of malignant
melanoma is increasing worldwide. In fact, the most re-
cent statistics predict approximately 69,000 new diagno-
ses and 8,700 deaths in the coming year in the United
States alone [1]. Once melanoma has metastasized it has
an extremely poor prognosis, with 5 year relative sur-
vival of just 15% [2]. In the past decade many genetic
alterations have been discovered that influence tumor
growth and spread. The knowledge gained during this
time has led to the recent approval of the BRAF inhibi-
tor PLX4032 (Zelboraf™) by the FDA for treatment of
late–stage melanoma [3].
The recent advances in next-generation sequencing
have allowed for the discovery of new causal variants* Correspondence: samuelsy@mail.nih.gov
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reproduction in any medium, provided the orand have also afforded us the opportunity to ask new
questions which could help dictate future treatment
strategies. In this study we use whole exome sequencing
to investigate two sets of distinct metastases to deter-
mine similarity.
Results/discussion
Exome sequencing and analysis
We performed whole exome sequencing of two distinct
metastases from two individuals with melanoma
(Additional file 1: Table S1). In both patients, metastatic
deposits were present in multiple anatomic sites, as is
typical for this form of cancer. Genomic DNA samples
derived from these metastases underwent whole exome
re-sequencing in parallel with their matched normal
DNA. Exonic sequences were enriched with Agilent's
SureSelect technology for targeted exon capture [4], tar-
geting 50 Mb of sequence from exons and flanking
regions in nearly 20,000 genes. Sequencing was per-
formed with the Illumina GAII platform, and reads were
aligned using ELAND (Illumina, Inc., San Diego, CA)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Whole exome capture and sequencing analysis of
melanoma samples derived from two sets of paired metastatic
tumors. Schematic overview of mutation identification approach of
the four whole exomes. Samples were obtained at The Surgery
Branch, National Cancer Institute.
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reference human genome (Build 36.1). On average, 11.7
Gb of sequence were generated per sample to a mean
depth of 103X to achieve exome builds with at least
87.5% of the targeted bases covered by high quality
genotype calls. To eliminate common germ line muta-
tions from consideration, we filtered variants observed
in dbSNP130 or in a high quality set of common var-
iants from the 1000 genomes project. To determine
which of these alterations were somatic, we compared
variants identified in the metastasis to their matched
normal tissue and removed any variants found in the
normal. From these putative alterations, 2356 potential
somatic mutations in 1256 different genes were identi-
fied in the samples sequenced.
A major challenge of such studies is discriminating
true mutations from the large number of possible se-
quence alterations identified. Previously determined cri-
teria were applied to discriminate between these
possibilities [5]. Briefly, a MPG score of 10 or greater
and a MPG/coverage ratio above 0.5 at a given position
in both matched tumors as well as the normal was
required to reliably evaluate an alteration. Once this cri-
terion was applied ~68% of the potential alterations were
removed, leaving 750 somatic base substitutions in 686
genes for further scrutiny. A total of 663 mutations were
heterozygous alterations and 87 were loss of heterozy-
gosity (Additional file 2: Table S2 & Additional file 3:
Table S3). Of these alterations, 490 caused amino acid
changes (non-synonymous), including 453 that were
missense, 28 nonsense and 5 occurring at splice sites.
There were 260 silent (synonymous) substitutions. A
total of 3 small deletions and 1 insertion were observed.
For a schematic of our analysis see Figure 1.
For each of the somatic mutations identified in the
lesions derived from the two patients, we determined
whether the same somatic mutation was present in ana-
tomically distinct metastases from the same patient. The
majority of the identified mutations were present in both
samples from a given patient (mean of 97%, range 96-
98%); (Tables 1 & 2). These data propose that most of
the somatically acquired mutations in these cancers
occur before the development of metastatic lesions and
might be considered potential founder mutations. Other
identified mutations were present in one of the metasta-
ses examined, but not the second metastasis (mean of
2.75%, range 1.46- 4.04%) (Tables 1 & 2). Many genes
previously implicated in melanoma or other cancer types
were seen to be mutated including the melanoma BRAF
[Swiss-Prot: P15056] mutation V600E which was found
in both metastases in the 98 set (Additional file 2: Table
S2). Also observed in this set were shared mutations in
MAPK10 [Swiss-Prot: P53779] which has been sug-
gested to be a candidate tumor suppressor [6], BRCA1[Swiss-Prot: P38398] [7], as well as ERBB4 [Swiss-Prot:
Q15303] [8], GRIN2A [Swiss-Prot: Q12879] [5], and
GRM3 [Swiss-Prot: Q14832] [9] which have previously
been reported to be mutated in melanoma. In the 130
set of metastases we find a frame shift mutation shared
by both in PTEN [Swiss-Prot: P60484] (Additional file 2:
Table S2), a known tumor suppressor [10]. Mutations in
genes proposed to play a role in cancer were also shared
in these metastases including ADAM29 [Swiss-Prot:
Q9UKF5] [11], ADAM19 [Swiss-Prot: Q9H013] [12],
and NOTCH2 [Swiss-Prot: Q04721] [13].
Our observed somatic mutations could either be
‘driver’ mutations that have a role in melanoma neopla-
sia or ‘passenger’ changes that are functionally inert. In
this whole exome screen, we identified 490 non-
synonymous and 260 synonymous mutations, yielding a
ratio of non-synonymous to synonymous changes (N/S
ratio) of ~1.9:1; which is not higher than the N/S ratio
of 2:1 predicted for non-selected passenger mutations
[14], suggesting that most of these alterations are likely
to be ‘passenger’ mutations. The number of C >T muta-
tions was significantly greater than the numbers of other
nucleotide substitutions, resulting in a high prevalence
of C:G >T:A transitions (P < 0.001) (Figure 2). Finally, a
total of 13 dinucleotide substitutions were observed, of
these, 12 were CC>TT/GG>AA changes, all consistent
with the previously documented ultraviolet light expos-
ure signature [15].









































130 set 305 173 478 3 3 0 1 302 169 99.02 97.69 98.54
Table shows total number of mutations found for each set. NS- non-synonymous mutation; S- synonymous mutation; NS + S total mutations both non-
synonymous and synonymous.








































98 set 185 87 272 4 1 3 3 178 83 96.22 95.40 95.96
Table shows total number of mutations found for each set. NS- non-synonymous mutation; S- synonymous mutation; NS + S total mutations both non-
synonymous and synonymous.
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We then used a novel approach to determine copy number
variants (CNV) from our exome data using aligned reads
for each tumor and normal pair. Genomic windows which
were defined by reading blocks of a fixed number of reads
in the normal sample allowed the generation of a pseudo-
CGH data output as described in the Methods section. Val-
idation of this methodology was performed to determineExome capture sequencing of 2 sets of paired metastatic tumors and 
their matched normal 
384X coverage, 89.9% bases with high quality genotype calls
Number of potential somatic mutations: 2356
Number of mutations with a 
MPG/Coverage ratio>=0.5: 750




mutations occurring in 
only a single metastatic 
tumor comprising 2% of 
nonsynonymous
mutations found 
Assemble sequence data 
(genome build hg18) and filter 
putative somatic mutations
480 Nonsynonymous mutations 
conserved between metastatic 
tumor pairs comprising 97.9% of 
nonsynonymous mutations 
found
Figure 2 Mutation spectra of single base pair substitutions in
melanoma whole exome sequencing. The number of each of the
six classes of base substitutions resulting in non-synonymous
changes in the whole exome screen is shown. A.) Mutation spectra
from 98 set; B.) Mutation spectra from 130 set.accuracy. A selection of genes identified as having copy
number differences in the 130 set was analyzed using qPCR
and this analysis yielded the results expected in 14 of 16
cases or 87.5% (Additional file 4: Figure S1). Using this
methodology we were able to compare our metastatic pairs
to their matched normal, as well as one metastasis to the
other. Through this analysis we were able to show similar,
concordance between 2 matched metastatic sets with a 10%
and 35% difference between the 130 set and 98 set metasta-
ses, respectively (Table 3 and Figure 3). Our CNV data
identified copy number changes in previously reported
regions of amplification and deletion in melanoma, such as
amplification of 6p, a region previously shown to contain
VEGF amplifications [16]. Also seen were copy number
losses in both arms of chromosome 10 (both metastatic
pairs) as well as loss in both arms of chromosome 9 (130
set and 14T sample) which have been previously reported
in 40 to 50% of melanoma samples [17]. Chromosome 9p
contains the CDKN2A [Swiss-Prot: P42771] locus, which is
a region known to encode tumor suppressor proteins
p16INK4 and p19ARF [18]. Loss of heterozygosity was also
determined for each sample by identifying SNVs that were
heterozygous in the normal sample for loss in the tumor.
To do this, we characterized the SNV in the tumor as
heterozygous (no LOH) or homozygous (LOH) and calcu-
lated a percentage of LOH for each sample in each region
Figure 3. Interestingly, differences can be seen with appar-
ent LOH not accompanied by any CNV differences. These
regions of copy neutral LOH (CN-LOH) have been seen in
solid cancers before [19], where it has been proposed that
errors in mitosis, double strand break repair, or exposure to
chemotherapeutic agents may provide a mechanism for in-
duction [20].Pathway enrichment analysis
Merging our SNV data with our CNV data we then per-
formed pathway analysis to search for enriched pathways
Table 3 Percent copy number difference
Set name % Copy number difference between the two metastases
130 10.86
98 34.95
Difference between the two metastases for each set: Total Mb different were calculated as described in methods at an absolute value of 0.35. The % difference
was calculated by taking the total Mb difference and dividing by the total genome size (build hg18).
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to be significantly enriched and shared between metasta-
ses in our 98 set (Figure 4). For our 130 set there were
only 2 enriched pathways shared between the two me-
tastases (Figure 5). This is due to fact that only two
pathways were enriched in 130T using this analysis.
When compared across tumors there were no pathways
found to be enriched in all tumors from both sets, once
again due to the lack of enriched pathways in sample
130T. There were however 4 pathways that were found
to be enriched in 3 of the samples (Figure 6). Among
these, Endothelin-1 and CREB signaling have previously
been suggested to play a role in melanoma [21,22]. Dif-
ferences seen between enriched pathways in matchedFigure 3 Circos plot depicting copy number in the genome. Outer ide
labels in Mb of physical distance. The data are represented in several tracks
variants showing LOH in 5 MB bins for the 130 metastatic sample. The nex
The data tracks depict relative copy number for the 130 met sample (in red
number differences between the two metastatic samples are highlighted in
for sample 14 met and then for sample 98 met. Finally, relative copy numb
light green highlights regions of significant copy number change. For all h
represents nearly all SNVs in the region showing LOH.tumors could be attributed to copy number differences
seen between the two samples due to large numbers of
of genes being found in regions of difference. A
complete list of pathways found to be enriched can be
found in the Additional file 5: Table S4.
Conclusion
Advances in next-generation Sequencing have allowed
researchers to affordably generate vast amounts of data
and address complex morbicentric genetics questions
with incredible sensitivity and robustness. In the present
study we used our data from whole exome sequencing
of two distinct metastases from the same patient to elu-
cidate the similarities and differences between theogram runs clockwise from chromosome 1 to chromosome X with
. The innermost track is a heat map representing the proportion of
t innermost track shows the LOH results for the 133 metastatic sample.
) and the 133 met sample (in black). Regions that show large copy
light green. Proceeding outward are two more heatmap LOH tracks
er profiles for samples 14 (in black) and 98 (in red) are shown; again,






















































































































































































































































































































































































Figure 5 Shared enriched pathways in the 130 set. Y axis represents the –log p-value for enrichment. Black horizontal line represents a –log
value of 1.3.






































































































Figure 6 Shared enriched pathways between the two sets. Y axis represents the –log p-value for enrichment. Black horizontal line represents
a –log value of 1.3.
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ful in selection of future treatment strategies.
Our data revealed similarities between the two paired
metastases at the level of somatic mutation and copy
number variations. These results would seem to indicate
that in both sets the metastases were derived from the
same parental clone that harbored the majority of the
genetic alterations and chromosomal instability. The
Clark model of melanoma progression holds that melan-
oma progression proceeds in a stepwise manner from
melanocyte to melanoma, categorized by numerous mo-
lecular changes which facilitate the transition through
each step [18]. Our results suggest that once the transi-
tion from the vertical growth phase to malignant melan-
oma occurs, a limited number of molecular changes
subsequently arise.
Despite these findings, further investigation is war-
ranted. Future work should include a side by side genetic
analysis of primary tumors pertaining to the metastatic
lesions as well as the analysis of more metastases per-
taining to the same patients derived from different
regions to see whether these results hold true. Nonethe-
less, these findings provide a proof-of-concept that se-
quencing of a limited number individual metastases may
be sufficient for targeting of melanoma driver mutations.Methods
Tumor tissues
Tissue and melanoma cell lines used for this study were
described previously [23]. The clinical information asso-
ciated with the melanoma tumors used in this study is
provided in Additional file 1: Table S1.
Exome capture
Exome capture was performed using the Sure Select
Human All Exon 50 Mb System (Agilent Technologies,
Santa Clara, CA). The manufacturer’s protocol for Sure
Select Human All Exon System (Illumina Paired-End Se-
quencing Library Prep), version 1.0.1 was used, with the
following modifications. Bioanalyzer steps were either
performed using agarose gel or omitted. The Illumina li-
brary preparation portion of the SureSelect protocol was
performed using the SPRIworks Fragment Library Sys-
tem (Beckman Coulter Genomics, Danvers, MA, USA)
according to manufacturer’s protocols.
Illumina sequencing
Sequencing was performed on the Illumina GAIIx plat-
form with version 5 chemistry and version 5 flowcells
according to the manufacturer’s instructions. 76 and 101
base paired-end reads were generated summary of
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Table S5.
Read mapping and variant analysis
Reads were initially aligned using ELAND (Illumina Inc.,
San Diego, CA). ELAND alignments were used to place
reads in bins of approximately 100,000 base pairs. Un-
mapped reads were placed in the bin of the mate pair if
the mate was mapped. Cross_match (Phil Green, http://
www.phrap.org) was utilized to align the reads assigned
to each bin to the corresponding ~100 kb of genomic
sequence. Cross_match alignments were converted to
the SamTools bam format, and then genotypes were
called using bam2mpg ([24], http://research.nhgri.nih.gov).
Bam2mpg was used to implement the Most Probable
Genotype (MPG) algorithm, a Bayesian based method
to determine the probability of each genotype given the
data observed at that position. The quality score repre-
sents the difference of the log likelihoods of the most
and second most probable genotype. The MPG was
divided by the coverage at each position to calculate the
MPG/coverage ratio.
To eliminate common germline mutations from con-
sideration, alterations observed in dbSNP130 or in a
high quality set of common variants from the 1000 gen-
omes 11_2010 data release project were removed. To
perform the 1000 genomes project filtering, low cover-
age genome data from 629 individuals was obtained
from the November 2010 data release of the 1000 gen-
omes project. From this list of variants we included
those positions called by at least 3 of the 4 analysis
methods used by the project. We further limited the list
to those variants above 5% minor allele frequency. Poly-
morphisms were further removed by examination of the
sequence of the gene in genomic DNA from matched
normal tissue. Genotypes were annotated as described in
[25].
Mutational analysis, confirmation, and determination
of somatic status were carried out to validate all muta-
tions found exclusively in one of the metastasis as previ-
ously described [8,23]. Sequence traces of the Validation
Screen were analyzed using the Mutation Surveyor soft-
ware package and all genes had 93% coverage or above
(SoftGenetics, State College, PA).
Copy number variation analysis
Copy number estimates for the tumor were generated
using aligned reads for each tumor and normal pair
(http://github.com/seandavi/ngCGH). Genomic windows
were defined by reading blocks of a fixed number of
reads (default 1000 reads) in the normal sample. Within
each defined genomic window, the number of reads in
the tumor was quantified. For each genomic window, a
log2 ratio was calculated between the number of readsin the tumor and the number of reads in the normal.
The window size mean, median, and median absolute
deviation (MAD) as well as the total number of windows
are summarized in Additional file 7: Table S6. Note that
these windows are not defined in regards to capture
regions but are distributed across the genome. The
resulting pseudo-CGH data output was segmented using
the circular binary segmentation (CBS) algorithm as
implemented in the DNAcopy Bioconductor package
(Venkatraman E. Seshan and Adam Olshen, DNAcopy:
DNA copy number data analysis. R package version
1.25.1.). The segmented data were used as input to the
Circos genome plotting algorithm [26]. Segmented
regions showing an absolute difference greater than 0.35
(in log2 units) between the two metastasis sample seg-
mentation results were considered to represent different
copy number as a log2 ratio of 0.35 of above represents
3 standard deviations when estimated by the derivative





Where ri is the log2 ratio for the i
th window and n is the
total number of windows. The denominator is just a
normalization parameter to make DLRS the same scale
as the standard deviation (when calculated on a
normally-distributed random variable).
Copy number validation
The results of CNV pseudo-CHG array were used to
create a Nexus Copy Number file (BioDiscovery) and
genes were randomly selected showing a CNV difference
between either one or both of the samples and the nor-
mal. Primers for the gene indicated were designed using
primer 3 with Line-1 primers used as controls for
normalization (Additional file 8: Table S7). 1 ng of each
sample gDNA was mixed with 2× Fast SYBR Green PCR
mix at a final volume of 10 μl in triplicate (Applied Bio-
systems cat # 4355612). qPCR analysis was done using
the ABI 7900HT Fast Real-Time PCR system (with a
standard program of stage 1: 50°C for 2 min; stage 2:
95°C for 10 min; stage 3: 40 cycles of 95°C for 15 s and
60°C for 1 min). Results were analyzed using Microsoft
Excel and SPSS.
Pathway analysis
CNV and SNV data were combined and IPA (Ingenuity
WSystems, www.ingenuity.com) was used to investigate
pathway enrichment for each tumor and set. The resulting
p-values were adjusted for multiple testing via the
benjamini-hochberg procedure. Adjusted p-values less
than 0.05 were considered significant. Common pathways
between tumors were merged using SequelPro and
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that were significant were plotted using the ggplot2 pack-
age in R.Additional files
Additional file 1: Table S1. Is a table listing the relevant clinical
information for the patients in each set.
Additional file 2: Table S2. Is a complete list of variants found in our
whole exome capture of the 98 set.
Additional file 3: Table S3. Is a complete list of variants found in our
whole exome capture of the 130 set.
Additional file 4: Figure S1. Contains Results of qPCR validation.
Additional file 5: Table S4. Is a complete list of pathways found to be
enriched in each individual tumor sample.
Additional file 6: Table S5. Is a summary of sequencing statistics for
each tumor.
Additional file 7: Table S6. Is summary of pseudo-CGH windows used
for deriving copy number from our exome sequencing.
Additional file 8: Table S7. Is complete list of primers used to evaluate
our CNV data trough real time PCR.Competing interests
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